Supernus Pharma (SUPN) Misses Q4 EPS by 54c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.02, $0.54 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $156 million versus the consensus estimate of $155.83 million.
GUIDANCE:
Supernus Pharma sees FY2024 revenue of $580-620 million, versus the consensus of $622.5 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
